

FOR IMMEDIATE RELEASE



BBB Therapeutics Appoints Jan van Heek as Chairman of the Supervisory Board

Leiden, the Netherlands, October 20, 2014 - BBB Therapeutics, a biopharmaceutical company pioneering treatments for devastating brain diseases, today announced the appointment of Jan van Heek as the Chairman of the Company's Supervisory Board effective October 17, 2014. Mr. van Heek has been a non-executive Board Member representing BBB Therapeutics' investor Antea Participaties since January of 2014. He will assume the leadership of the Board from Patrick Krol, Managing Partner at Aescap Venture, who has served as BBB Therapeutics' Chairman since 2007. Mr. Krol will remain on the Board as a non-executive Member.

"Jan's vast experience as a leading executive for one of the most successful biopharmaceutical companies in the history of our industry will be vital to BBB Therapeutics as the Company advances its clinical candidates to treat key indications in neuro-oncology and neuroinflammation," commented Dr. Anders Harfstrand, CEO. "We thank Patrick for leading the Board for the past seven years and supporting the Company through its development. We look forward to his continued contributions."

Mr. van Heek brings over 25 years of executive experience in the biotech industry to the Company. He is principal and partner of BioPoint Group, where he advises biotechnology and other healthcare companies in commercial strategy development, financing and business development activities. From 1991 until 2009, Mr. van Heek held several executive positions at Genzyme, including his tenure as Executive Vice President of Genzyme Corporation, where he established Genzyme's European and international offices and headed the global Therapeutics Group in the US. Mr. van Heek has played a key role in building Genzyme's broad portfolio of businesses and manufacturing structures worldwide. Prior to Genzyme, he held various management positions at Baxter Healthcare Corporation in Europe and in the US. Mr. van Heek has served as Chairman of the Board of Biovex and as non-executive Member of the Boards of PanGenetics, ViaCell and Zelos Therapeutics. He is currently a non-executive Board Member and Chairman of the Audit Committee of Amarin Corporation and has recently also joined the Board of Minerva Neurosciences. Mr. van Heek holds an MBA from the University of St.Gallen - School of Management, Economics, Law, Social Sciences and International Affairs and an Executive degree from Stanford University Graduate School of Business.

About BBB Therapeutics

BBB Therapeutics is pioneering innovative therapeutics to treat severe brain disorders for which there are currently limited treatment options. We are advancing a clinical pipeline of product candidates initially focused on treating brain metastases and primary brain tumors as well as indications in neuroinflammation. Our proprietary liposomal G-Technology® facilitates entry of drugs into the brain while simultaneously enabling sustained delivery of systemically administered therapeutics.

Corporate Contact:

Dr. Anders Harfstrand, CEO
BBB Therapeutics
Direct: +31 62 482 5973

aharfstrand@bbbtx.com
J.H. Oortweg 19
2333 CH Leiden
The Netherlands
www.BBBtherapeutics.com

Media Contact:

Gretchen Schweitzer
MacDougall Biomedical Communications
Direct: +49 172 861 8540
Main: +1 781 235 3060
gschweitzer@macbiocom.com